-
Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Gerald Illerhaus, Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer, +43 more
44citations -
The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia2023 Blood article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Marja Hakkarainen, Ilse Kaaja, Suvi P. M. Douglas, Thomas J. Vulliamy, Inderjeet S Dokal, Jean Pierre Soulier, +23 more
42citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations -
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Christian Straka, Kerstin Schaefer‐Eckart, Bernd Hertenstein, Florian C. Bassermann, Hans Jürgen Salwender, Christian H. Langer, +32 more
17citations -
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
Andreas Burchert, Susanne Saußele, Stephan Metzelder, Andreas Hochhaus, Norbert Gattermann, Martina Margrit Crysandt, +27 more
13citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations